Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT05005975 |
| Consolidated Lead Sponsor | Tanabe Pharma America |
| Therapeutic Condition Cohort | Rare Genetic, Women's Health, and Other |
| Clinical Trial Phase | Phase III |
| Overall Recruitment Status | ACTIVE NOT RECRUITING |
| Registered Enrollment | 286 participants (ACTUAL) |
| Registered Start Date | 2021-08-10 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| UCSF Medical Center and Helen Diller Cancer Center | San Francisco, CA | Open Hospital Dossier -> |
| Massachusetts General Hospital | Boston, MA | Open Hospital Dossier -> |
| Henry Ford Health System | Detroit, MI | Open Hospital Dossier -> |
| Mount Sinai Hospital and Icahn School of Medicine | New York, NY | Open Hospital Dossier -> |
Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.